https://orcid.org/0000-0003-4985-9855
References
- Gupta A, Gupta V. Tubercular posterior uveitis. Int Ophthalmol Clin. 2005;45:71–88. doi:10.1097/01.iio.0000155934.52589.e3.
- Gupta V, Gupta A, Rao NA. Intraocular tuberculosis—an update. Surv Ophthalmol. 2007;52:561–587. doi:10.1016/j.survophthal.2007.08.015.
- Oehlers S, Cronan M, Scott N, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature. 2015;517(7536):612–615. doi:10.1038/nature13967.
- Gupta V, Gupta A, Rao NA. Intraocular tuberculosis—an update. Surv Ophthalmol. 2007;52(6):561–587. doi:10.1016/j.survophthal.2007.08.015.
- Bansal R, Beke N, Sharma A. Gupta A Intravitreal bevacizumab as an adjunct in the management of a vascular choroidal granuloma. BMJ Case Rep. 2013;6:201.
- Jain S, Bajgai P, Tigari B, et al. Bevacizumab for paradoxical worsening treatment adjunct in HIV patient with choroidal tuberculoma. J Ophthalmic Inflamm Infect. 2016;6:42.
- Invernizzi A, Franzetti F, Viola F, Meroni L, Staurenghi G. Optic nerve head tubercular granuloma successfully treated with anti-VEGF intravitreal injections in addition to systemic therapy. Eur J Ophthalmol. 2015;25:270–272. doi:10.5301/ejo.5000528.
- Thayil SM, Albini TA, Nazari H, et al. Local ischemia and increased expression of vascular endothelial growth factor following ocular dissemination of mycobacterium tuberculosis. PLoS ONE. 2011;6:e28383. doi:10.1371/journal.pone.0028383.